Studies have shown that transgene expression rates and activity patterns of independently transformed wheat lines with constitutive ubiquitin promoters can vary [40].
For example, we have seen that two cell types with very different transgene expression rates can show statistically similar nanoparticle uptake rates.
Combining the sarcoma virus-derived promoter with a modified feline endogenous retrovirus envelope glycoprotein yielded in superior transgene expression and transduction rates.
Line 1, which had a lower myc17ER transgene expression, showed a raised proliferative rate when compared with line 2. Conversely, line 2 had a higher transgene expression level and seemed to induce a higher apoptotic rate than line 1 (Figs 5, 6).
Quantification of BrdU incorporation after Myc induction (Fig. 4B) revealed that line 1, which has a lower transgene expression level, had a higher rate of proliferation compared with line 2. Approximately 3% of liver cells in line 1 were proliferating after Myc activation, whereas, in line 2, only 2% of all cells were BrdU positive.
Therefore, we investigated the effects of infusion rate, volume, and dose on transgene expression in liver and tumor tissues after intratumoral infusion of an adenoviral vector encoding luciferase.
Transgene expression and phenotype under control conditions of transgenic Arabidopsis seedlings expressing the yeast Tpo1p or Pdr5p transporters.
The non-viral SB transposon/transposase system has many advantages over other non-viral DNA vectors, such as higher transgene integration rate, without plasmid sequences integration that silence transgene expression and no integration of transgene concatemers.
However, the low transduction rate of viral vectors in vivo confines therapeutic transgene expression to only those cells along the injected needle track due to the viral inability to pass the transgene to neighboring cells.
Pathology propagated from transgene-expressing neurons to adjacent brain regions lacking any detectable transgene expression.
